Latest fiscal year 2025 · computed deterministically from XBRL 10-K data · coverage 100%
In fiscal 2025, TEVA PHARMACEUTICAL INDUSTRIES LIMITED reported revenue of $17.26B, up 4.3% year over year. Operating margin was 12.5% and net margin 8.2%, on a free-cash-flow margin of 6.7% with capital expenditure at 2.9% of revenue. Every figure is computed directly from TEVA's SEC XBRL 10-K filing — deterministic, with no estimates.
| Fiscal year | Revenue | Op margin | Net margin |
|---|---|---|---|
| FY2025 | $17.26B | 12.5% | 8.2% |
| FY2024 | $16.54B | -1.8% | -9.9% |
| FY2023 | $15.85B | 2.7% | -3.5% |
| FY2022 | $14.93B | -14.7% | -16.4% |
| FY2021 | $15.88B | 10.8% | 2.6% |
How does TEVA compare against its actual peer set?
A CompsDesk subscription covers unlimited benchmark packs on any covered company: up to 19 metrics (6 core guaranteed) × up to 5 fiscal years × up to 12 chosen peers, percentile placement, the subject's figures cited to their SEC tag, form and period with every company identified by its CIK, PDF-ready HTML + CSV, generated on demand.
Related in the same sector: AAWH · ABBV · ABCL · ABT · ABUS · ACAD
Source: SEC EDGAR XBRL (10-K filings), latest filed values. "n/a" = not disclosed under mapped tags — never estimated. Informational benchmarking, not investment advice. © CompsDesk / Sam Arora.